Pramlintide amylin analog data

AMLN announced that Phase II results of Pramlintide in 200 patients using insulin showed improved glucose control (see BioCentury Extra, Aug. 8). All three dosing regimens gave statistically significant lower levels of fructosamine, an indicator of average glucose concentration, compared to placebo. The levels were assessed before and after the one-month study. ...